PO.IM02.01 · 免疫学

甲状腺激素调节肺免疫微环境以调控乳腺癌转移

Thyroid hormones modulate the lung immune microenvironment to regulate breast cancer metastasis

海报缩略图:甲状腺激素调节肺免疫微环境以调控乳腺癌转移
编号 185 展板 5 时间 4/19 02:00–05:00 区域 Section 9 主讲 Helena Sterle, PhD
分会场 Inflammation and Cancer Progression
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Gonzalo Gonzalez, Florencia Menay, Johanna Díaz Albuja, María M. Debernardi, Lucero Alvarado, María A. Paulazo, Cinthia Rosemblit, Florencia Cayrol, Graciela A. Cremaschi, Helena A. Sterle

Instituto de Investigaciones Biomédicas (BIOMED-UCA-CONICET), Buenos Aires, Argentina

摘要 Abstract

中文摘要
甲状腺疾病和乳腺癌(BC)在女性中均更为普遍,然而甲状腺激素(THs)对BC进展和转移的影响仍知之甚少。我们此前显示,荷有4T1 BC肿瘤的甲状腺功能亢进小鼠表现出加速的原发肿瘤生长,而甲状腺功能减退小鼠肿瘤生长较慢但肺转移数量更多。为阐明这些效应背后的机制,我们首先使用划痕愈合实验评估了THs对4T1细胞迁移的直接影响。随后,我们检测了甲状腺状态对肺部免疫亚群和细胞因子环境的影响。为此,雌性Balb/c小鼠通过每日给予甲状腺素(T4)4周诱导为甲状腺功能亢进状态,通过丙硫氧嘧啶(PTU)2周诱导为甲状腺功能减退状态,或通过在PTU处理后补充三碘甲状腺原氨酸(T3)诱导为恢复的甲状腺功能正常状态。随后将小鼠原位或静脉接种4T1细胞。在体外,T3和T4并未改变4T1细胞迁移,表明THs通过宿主机制间接调控转移。在体内,甲状腺状态深刻改变了肺部免疫格局。甲状腺功能亢进小鼠的肺部表现出细胞毒性T淋巴细胞、自然杀伤(NK)细胞和B细胞比例增加,伴随更高的IFN-gamma和IL-2水平(p<0.05),与更具细胞毒性的微环境一致。相反,甲状腺功能减退小鼠的肺部显示出髓源性抑制细胞(MDSC)增加以及CCL5、CCL17和CCL22水平升高(p<0.05),这些与免疫抑制增强、细胞募集和转移形成相关。这些改变可通过短期T3治疗逆转。此外,静脉接种4T1细胞的甲状腺功能亢进小鼠也表现出NK细胞水平升高,而甲状腺功能减退小鼠表现出更高的MDSC,提示这一效应独立于原发肿瘤。总之,我们的发现表明甲状腺激素不直接影响BC细胞迁移,但关键性地调节转移靶器官的免疫微环境。甲状腺功能亢进促进可能抑制转移的细胞毒性和体液免疫反应,而甲状腺功能减退驱动有利于肺定植的免疫抑制性细胞因子网络。理解甲状腺激素如何影响免疫反应,是开发更有效乳腺癌治疗策略的关键。
查看英文原文 English abstract
Thyroid disorders and breast cancer (BC) are both more prevalent in women, yet the influence of thyroid hormones (THs) on BC progression and metastasis remains poorly understood. We previously showed that hyperthyroid mice bearing 4T1 BC tumors display accelerated primary tumor growth, whereas hypothyroid mice develop slower-growing tumors but a higher number of lung metastases. To elucidate the mechanisms underlying these effects, we first evaluated the direct influence of THs on 4T1 cell migration using wound-healing assays. We then examined the impact of thyroid status on the immune subpopulations and cytokine milieu in the lungs. For this, female Balb/c mice were induced to a hyperthyroid state by daily thyroxine (T4) administration for 4 weeks, to a hypothyroid state by propylthiouracil (PTU) for 2 weeks, or to a reverted euthyroid condition by supplementing triiodothyronine (T3) after PTU treatment. Mice were subsequently inoculated with 4T1 cells orthotopically or intravenously. In vitro, T3 and T4 did not modify 4T1 cell migration, indicating that THs regulate metastasis indirectly through host mechanisms. In vivo, thyroid status profoundly altered the pulmonary immune landscape. Lungs from hyperthyroid mice exhibited increased proportions of cytotoxic T lymphocytes, natural killer (NK) cells, and B cells, accompanied by higher IFN-gamma and IL-2 levels (p < 0.05), consistent with a more cytotoxic microenvironment. In contrast, lungs from hypothyroid mice displayed increased myeloid-derived suppressor cells (MDSCs) and elevated CCL5, CCL17, and CCL22 levels (p < 0.05), which are associated with heightened immunosuppression, cell recruitment, and metastasis formation. These alterations were reverted by short-term T3 treatment. Moreover, hyperthyroid mice intravenously inoculated with 4T1 cells also showed increased NK cell levels, whereas hypothyroid mice exhibited higher MDSCs, suggesting that this effect is independent of the primary tumor. Collectively, our findings demonstrate that thyroid hormones do not directly affect BC cell migration but critically modulate the immune microenvironment in metastatic target organs. Hyperthyroidism promotes cytotoxic and humoral immune responses that may restrain metastasis, while hypothyroidism drives an immunosuppressive cytokine network that favors lung colonization. Understanding how thyroid hormones influence immune responses is key to developing more effective therapeutic strategies for breast cancer.
利益披露 Disclosure
G. Gonzalez, None.. F. Menay, None.. J. Díaz Albuja, None.. M. M. Debernardi, None.. L. Alvarado, None.. M. A. Paulazo, None.. C. Rosemblit, None.. F. Cayrol, None.. G. A. Cremaschi, None.. H. A. Sterle, None.

← 返回 AACR 2026 检索